Abstract: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.
Type:
Grant
Filed:
November 26, 2009
Date of Patent:
September 13, 2016
Assignee:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
Inventors:
Monsef Benkirane, Robinson Triboulet, Christine Chable-Bessia, Yamina Bennasser, Daniel Latreille, Oussama Meziane, Pascal Barbry, Bernard Mari, Jacques Reynes
Abstract: The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.
Abstract: The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.
Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.
Abstract: The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
Type:
Grant
Filed:
November 21, 2014
Date of Patent:
July 12, 2016
Assignee:
Trustees of Dartmouth College
Inventors:
Ta-Yuan Chang, Catherine C. Y. Chang, Yohei Shibuya, Zhaoyang Niu
Abstract: The present invention relates to a novel customized sRNA that reduces gene expression in prokaryotic cells, a preparation method thereof, and the use thereof, and more particularly to a synthetic sRNA comprising an Hfq binding site, derived from the sRNA of any one of MicC, SgrS and MicF, and a region that base-pairs with the target gene mRNA, and to a preparation method thereof and the use thereof. The synthetic sRNA according to the invention has an advantage in that the degree of inhibition of the target gene can be controlled by regulating the ability of the synthetic sRNA to bind to the mRNA of the target gene. The use of the synthetic sRNA that regulates the expression of the target gene makes it possible to effectively construct a recombinant microorganism without using a conventional gene deletion method and to reduce the expression of the target gene, and thus the synthetic sRNA is useful for the production of recombinant microorganisms.
Type:
Grant
Filed:
January 11, 2013
Date of Patent:
July 12, 2016
Assignee:
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
Type:
Grant
Filed:
May 29, 2014
Date of Patent:
July 12, 2016
Assignee:
Trustees of Dartmouth College
Inventors:
Ta-Yuan Chang, Catherine C. Y. Chang, Yohei Shibuya, Zhaoyang Niu
Abstract: The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.
Type:
Grant
Filed:
January 27, 2015
Date of Patent:
July 5, 2016
Assignee:
SomaLogic, Inc.
Inventors:
Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold, Thale C. Jarvis, Jeffrey D. Carter
Abstract: The present invention is directed to compositions methods and kits for regulation of gene therapies, including, without limitation, reversible gene therapies and allele-specific therapies.
Type:
Grant
Filed:
November 3, 2006
Date of Patent:
June 28, 2016
Assignee:
Medtronic, Inc.
Inventors:
William F. Kaemmerer, Eric Burright, Jennifer Heisel, Deepak Thakker
Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.
Abstract: This invention relates to methods and compositions of oligonucleotide constructs having a photocleavable linker. Specifically, provided herein are methods and compositions utilizing a photocleavable linker, which when exposed to light modulates the expression of genes.
Type:
Grant
Filed:
November 27, 2007
Date of Patent:
June 21, 2016
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: This invention relates to compounds, compositions, and methods useful for reducing MYC target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
May 24, 2016
Assignee:
Dynavax Technologies Corporation
Inventors:
Franck Barrat, Robert L. Coffman, Cristiana Guiducci
Abstract: The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV).
Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
Type:
Grant
Filed:
September 13, 2007
Date of Patent:
May 10, 2016
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Hua Gu, Richard Hodes, Jeffrey J. Chiang, Ihnkyung Jang
Abstract: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.
Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
Type:
Grant
Filed:
August 27, 2008
Date of Patent:
May 3, 2016
Assignee:
1 GLOBE HEALTH INSTITUTE LLC
Inventors:
Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
Abstract: An aptamer-based solid-state electrochemical biosensor for label-free detection of Salmonella enterica serovars utilizing immobilized aptamers. The device is realized by forming a matrix array of parallel capacitors, thus allowing the realization of low-cost, portable, fully integrated devices. Protein-aptamer binding modulates the threshold voltage of a circuit, changing the impedance (capacitance) of the circuit. This circuit is further characterized by an electrode coded with a p-Si substrate, enhancing the affinity between the Salmonella outer membrane proteins (OMPs) and the aptamer. An aptamer embedded detection plate is configured within a testing lid device that fits a standard, commercially available polymer specimen jar. A sample is mixed with broth for incubation and cultivation of any present Salmonella bacteria to obtain acceptable concentration of the pathogen for testing. The information obtained can then be transmitted by wireless network.
Abstract: Pharmaceutical compositions that comprise an siRNA molecule used in the treatment of diseases caused by flavivirus infection and methods of their use are disclosed. The pharmaceutical compositions treat diseases caused by yellow fever virus, West Nile virus, and dengue virus and include a single pharmaceutical composition active against all four dengue virus serotypes.